PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this clinical research study was to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are beginning allopurinol treatment for gout. Subjects will participate in this study for approximately 22 weeks. Rilonacept is being studied for use in preventing allopurinol-induced gout flares.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Regeneron Pharmaceuticals
• Treatments: Allopurinol; Rilonacept

Criteria

Inclusion Criteria:

• Male or female 18 to 80 years of age;

• Previously met the preliminary criteria of the American Rheumatism Association (ARA) for the classification; of the acute arthritis of primary gout;

• At least 2 gout flares in the year prior to the screening visit;

• Serum uric acid greater than or equal to 7.5 mg/dL at the screening visit;

Exclusion Criteria:

• Acute gout flare within 2 weeks of the screening visit or during screening;

• Persistent chronic or active infections;

• History of an allergic reaction to allopurinol;

• History or presence of cancer within 5 years of the screening visit;

• Previous exposure to Rilonacept;

• Use of allopurinol, benzbromarone, febuxostat, probenecid or sulfinpyrazone within 3 months prior to the screening visit.